Inflammatory Bowel Disease Market Set to Undergo Transformative Growth by 2034 - DelveInsight | Genentech, AbbVie, Boehringer Ingelheim, Gilead Sciences, Arena Pharmaceuticals, Eli Lilly, AstraZeneca

Inflammatory Bowel Disease, encompassing ulcerative colitis and Crohn's disease, continues to impose a significant burden on patients and healthcare systems worldwide. Driven by an increasing prevalence across industrialized nations, alongside rising awareness and early diagnosis, the IBD market is witnessing a paradigm shift from conventional therapies to next-generation biologics, small molecules, and personalized approaches.

DelveInsight's comprehensive report, "Inflammatory Bowel Disease - Market Insight, Epidemiology, and Market Forecast - 2034," delivers a strategic analysis of the current and future IBD market landscape. Covering major markets across the 7MM (the US, EU4, the UK, and Japan), the report delves into epidemiological segmentation, treatment trends, and pipeline innovations. With growing research into gut microbiome modulation, novel anti-inflammatory mechanisms, and biosimilars, the IBD space is poised for continued clinical and commercial expansion through 2034.

Request a sample and uncover the latest breakthroughs shaping the inflammatory bowel disease market landscape and future outlook @ https://www.delveinsight.com/sample-request/inflammatory-bowel-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Some of the key insights of the Inflammatory Bowel Disease Market Report:
• The inflammatory bowel disease market is expected to witness significant growth at a notable CAGR throughout the forecast period, 2024-2034.
• In 2023, the US accounted for nearly 50% of the diagnosed prevalent cases of inflammatory bowel disease across the 7MM, with cases expected to rise during the forecast period.
• Moderate to severe IBD cases were higher than mild cases in the US in 2023.
• The 18-44 years age group had the highest number of IBD cases in the US in 2023.
• Crohn's disease is generally more severe than ulcerative colitis but slightly less common, most often diagnosed in people aged 20 to 30.
• In February 2025, Bracco Imaging received FDA Fast Track designation for BR55, an imaging agent to detect active bowel inflammation in Crohn's disease.
• In January 2025, Eli Lilly's OMVOH (mirikizumab) was approved by the FDA for treating moderately to severely active Crohn's disease in adults, following its earlier approval for ulcerative colitis in October 2023.
• In December 2024, Celltrion's STEQEYMA (ustekinumab-stba), a biosimilar to STELARA, was approved by the FDA for Crohn's disease and ulcerative colitis.
• In May 2024, Johnson & Johnson submitted applications to the EMA to expand TREMFYA (guselkumab) for the treatment of moderately to severely active ulcerative colitis and Crohn's disease.
• Emerging therapies for Inflammatory Bowel Disease include Mirikizumab, RHB-104, ZEPOSIA (ozanimod; RPC1063), RHB-104, Tulisokibart, Duvakitug, AGMB-129, ABX464, Cobitolimod, PRA023, Remestemcel-L, PF-06651600, and others.
• Key companies involved in the treatment of Inflammatory Bowel Disease include Takeda Pharmaceutical, Janssen Pharmaceuticals, Hoffmann-La Roche, Genentech, AbbVie, Boehringer Ingelheim, Gilead Sciences, Arena Pharmaceuticals, Eli Lilly, AstraZeneca, and others.

To know in detail about the inflammatory bowel disease market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: https://www.delveinsight.com/report-store/inflammatory-bowel-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Inflammatory Bowel Disease Overview
Inflammatory bowel disease (IBD) includes Crohn's disease and ulcerative colitis, both marked by chronic gastrointestinal inflammation. While symptoms overlap, Crohn's can affect any part of the digestive tract-often the ileum and colon-with patchy, full-thickness inflammation. In contrast, ulcerative colitis is limited to the colon and r3ctum, causing continuous inflammation of the inner lining.
IBD diagnosis relies on a combination of methods to assess inflammation and distinguish between subtypes. Endoscopy and colonoscopy offer direct visualization, while MRI and CT scans help evaluate internal damage without radiation. Contrast radiography is useful in Crohn's for detecting strictures and fistulas. Stool tests identify inflammation markers, and blood tests assess anemia, immune activity, and nutrient levels. Together, these tools guide accurate diagnosis and personalized treatment planning.

Get a free sample for the inflammatory bowel disease market forecast, size & share analysis report: https://www.delveinsight.com/sample-request/inflammatory-bowel-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Inflammatory Bowel Disease Epidemiology
The epidemiology section offers an overview of historical, current, and projected trends in the seven major countries (7MM) from 2020 to 2034. It helps identify the factors influencing these trends by examining various studies and perspectives from key opinion leaders. Additionally, the section provides an in-depth analysis of the diagnosed patient population and future trends.
Inflammatory Bowel Disease Epidemiology Segmentation:

The Inflammatory Bowel Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM, segmented into:
• Total Diagnosed Prevalent Cases of Inflammatory Bowel Disease
• Type-Specific Cases of Inflammatory Bowel Disease
• Severity-Specific Cases of Inflammatory Bowel Disease
• Age-Specific Cases of Inflammatory Bowel Disease
• Treatable cases of Inflammatory Bowel Disease

Inflammatory Bowel Disease Drugs Uptake and Pipeline Development Activities
The drug uptake section examines the adoption rates of newly launched and upcoming inflammatory bowel disease drugs over the study period. It analyzes the uptake of these treatments, evaluating how patients adopt these therapies and the sales performance of each drug. This section provides a comprehensive overview of the factors that influence the acceptance and success of inflammatory bowel disease treatments on the market.

In addition, the therapeutics assessment section highlights the inflammatory bowel disease drugs that have experienced the fastest uptake. It delves into the key drivers behind their widespread use and provides a comparison of market share among these drugs. This section helps identify which therapies are gaining traction and the reasons behind their rapid adoption.

The report further explores the pipeline for inflammatory bowel disease, providing insights into therapeutic candidates at various stages of development. It identifies the key companies involved in developing targeted treatments for inflammatory bowel disease. The report also covers recent developments in the field, including collaborations, mergers, acquisitions, licensing agreements, and other significant updates on emerging therapies for Inflammatory Bowel Disease.

Explore how emerging inflammatory bowel disease therapies are aligning with evolving patient populations @ https://www.delveinsight.com/report-store/inflammatory-bowel-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Inflammatory Bowel Disease Market Outlook
Over the past decade, advancements in therapies like HUMIRA (AbbVie), REMICADE (Janssen), and ENTYVIO (Takeda) have significantly transformed the treatment landscape for inflammatory bowel disease (IBD), enabling many patients to achieve clinical remission, mucosal healing, and avoid surgical interventions such as colectomy. Emerging approaches like dual-targeted therapy are showing promise for refractory cases, potentially improving long-term outcomes and quality of life. Additionally, the success of bispecific antibodies in oncology is now inspiring innovation in immune-mediated conditions like IBD.

The limited treatment options for relapsed or refractory ulcerative colitis highlight a substantial opportunity for therapeutic development. With the rising prevalence of IBD, improved diagnostic capabilities, an aging population, therapeutic advancements, and increased awareness and access to healthcare across regions, the IBD market is expected to experience sustained growth between 2024 and 2034.

Inflammatory Bowel Disease Market Drivers
• The increasing global prevalence of IBD, driven by factors like urbanization, diet, and genetic predisposition, is fueling the demand for effective treatment options.
• The development of new biologics and targeted therapies, including dual-targeted treatments and bispecific antibodies, is enhancing treatment efficacy and offering new hope for refractory cases.

Inflammatory Bowel Disease Market Barriers
• The high cost of biologic therapies and specialized treatments can limit accessibility for patients, especially in low-income regions.
• Despite advancements, treatment options for patients with relapsed or refractory IBD remain limited, presenting challenges in managing more severe cases.

Scope of the Inflammatory Bowel Disease Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Inflammatory Bowel Disease Companies: Takeda Pharmaceutical, Janssen Pharmaceuticals, Hoffmann-La Roche, Genentech, AbbVie, Boehringer Ingelheim, Gilead Sciences, Arena Pharmaceuticals, Eli Lilly, AstraZeneca, and others.
• Key Inflammatory Bowel Disease Therapies: Mirikizumab, RHB-104, ZEPOSIA (ozanimod; RPC1063), RHB-104, Tulisokibart, Duvakitug, AGMB-129, ABX464, Cobitolimod, PRA023, Remestemcel-L, PF-06651600, and others.
• Inflammatory Bowel Disease Therapeutic Assessment: Inflammatory Bowel Disease currently marketed, and Inflammatory Bowel Disease emerging therapies
• Inflammatory Bowel Disease Market Dynamics: Inflammatory Bowel Disease market drivers and Inflammatory Bowel Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Inflammatory Bowel Disease Unmet Needs, KOL's views, Analyst's views, Inflammatory Bowel Disease Market Access and Reimbursement

To learn more about inflammatory bowel disease companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/inflammatory-bowel-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Inflammatory Bowel Disease Market Report Introduction
2. Executive Summary for Inflammatory Bowel Disease
3. SWOT analysis of Inflammatory Bowel Disease
4. Inflammatory Bowel Disease Patient Share (%) Overview at a Glance
5. Inflammatory Bowel Disease Market Overview at a Glance
6. Inflammatory Bowel Disease Disease Background and Overview
7. Inflammatory Bowel Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Inflammatory Bowel Disease
9. Inflammatory Bowel Disease Current Treatment and Medical Practices
10. Inflammatory Bowel Disease Unmet Needs
11. Inflammatory Bowel Disease Emerging Therapies
12. Inflammatory Bowel Disease Market Outlook
13. Country-Wise Inflammatory Bowel Disease Market Analysis (2020-2034)
14. Inflammatory Bowel Disease Market Access and Reimbursement of Therapies
15. Inflammatory Bowel Disease Market Drivers
16. Inflammatory Bowel Disease Market Barriers
17. Inflammatory Bowel Disease Appendix
18. Inflammatory Bowel Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.